After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics (FULC) has experienced a significant 21.5% stock price drop over the past four weeks. However, technical analysis using the Relative Strength Index (RSI) indicates the stock is now in oversold territory, suggesting a potential trend reversal. This technical signal is supported by strong fundamental indicators, including a 9.6% increase in consensus EPS estimates by analysts and a Zacks Rank #2 (Buy).
Fulcrum Therapeutics, Inc. - Common Stock (NQ: FULC)
This article provides a list of recent news and analyst coverage for Fulcrum Therapeutics, Inc. (Nasdaq: FULC). It highlights several investigations into potential securities law violations, reports on the company's financial results and upcoming conference calls, and mentions various analyst ratings and stock performance news. A significant event noted is the plummeting of shares due to the FDA placing a clinical hold on its sickle cell disease study.
Nantahala Capital files: 3,050,040 shares (4.58%) in THERAPEUTICS, INC. (FULC)
Nantahala Capital Management, LLC and its affiliated reporting persons have disclosed a beneficial ownership of 3,050,040 shares, representing 4.58% of the common stock in Fulcrum Therapeutics, Inc. (FULC), as of March 31, 2026. This is a passive investment filing (SCHEDULE 13G/A) indicating no intent to influence control of the company. The filing notes shared voting and dispositive power over these shares by Nantahala, Wilmot B. Harkey, and Daniel Mack.
Fulcrum Therapeutics (FULC) amendment shows 5.25M-share, 7.9% position
Fulcrum Therapeutics (FULC) has filed an Amendment No. 1 to a Schedule 13G, revealing that TCG Crossover II, its general partner TCG Crossover GP II, and Chen Yu collectively hold 5,250,000 shares, representing 7.9% of the outstanding common stock as of April 20, 2026. The filing clarifies beneficial ownership and explicitly disclaims group status among the reporting persons. This administrative amendment updates the public record regarding a significant passive investment in Fulcrum Therapeutics.
Bank of America Securities Keeps Their Sell Rating on Fulcrum Therapeutics (FULC)
Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Fulcrum Therapeutics (FULC) with a price target of $8.00, following the company's shares closing at $7.01. This contrasts with an overall analyst consensus of Moderate Buy for FULC, with a higher price target of $18.44. Fulcrum Therapeutics reported a GAAP net loss of $18.89 million for the quarter ending March 31, an increase from $17.66 million in the prior year.
Fulcrum Therapeutics (FULC.US) is scheduled to release its earnings report before the market opens on April 27.
Fulcrum Therapeutics (FULC.US) is set to release its earnings report before the market opens on April 27. This announcement provides investors and analysts with a specific date to anticipate the company's latest financial results. The earnings release will cover the company's performance leading up to the report date.
Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy Recommendation
Truist Securities has initiated coverage of Fulcrum Therapeutics (FULC) with a Buy recommendation. This news reflects a positive outlook from the investment firm regarding the company's prospects.
Two new Fulcrum hires get 55,500 stock options at $7.02 a share
Fulcrum Therapeutics granted 55,500 inducement stock options to two new employees at an exercise price of $7.02 per share. These options, part of the company's 2022 Inducement Stock Incentive Plan, vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and is considered a standard practice for attracting new talent in the biotech industry.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced that it granted non-statutory stock options to two new employees. These grants were made under the company's 2022 Inducement Stock Incentive Plan as a material inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants total 55,500 options with an exercise price of $7.02 per share and a four-year vesting schedule.
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Sell at Wall Street Zen
Wall Street Zen upgraded Fulcrum Therapeutics (NASDAQ:FULC) from a "strong sell" to a "sell" rating. Despite this, the stock holds a "Moderate Buy" average rating from analysts with an average price target of $19.00, though some long-term EPS forecasts have been lowered. The company recently beat quarterly EPS estimates and has significant institutional ownership.
[ARS] Fulcrum Therapeutics, Inc. SEC Filing
This article announces an ARS SEC Filing by Fulcrum Therapeutics, Inc. (FULC) on April 30, 2026, which is available as a PDF document. It also provides an overview of FULC's stock performance, market data, and recent news and SEC filings, indicating a low filing impact and neutral sentiment.
Fulcrum Therapeutics (FULC) director receives 64,000 stock options at $8.08 strike price
Fulcrum Therapeutics (FULC) director Joshua Lehrer-Graiwer was granted 64,000 stock options with an exercise price of $8.08 per share. These options, part of a compensation package, will vest in equal monthly installments until April 23, 2029, contingent on his continued service. The options are set to expire on April 22, 2036.
Fulcrum Therapeutics (NASDAQ: FULC) director files Form 3 with no shares owned
Fulcrum Therapeutics director Joshua Lehrer-Graiwer has filed an initial ownership report (Form 3) indicating he currently holds no securities in the company. This filing establishes his baseline ownership as zero shares beneficially owned, which is a standard procedure for new insiders to report their initial position. The Form 3 details his directorship and confirms no direct or indirect beneficial ownership at this time.
[DEF 14A] Fulcrum Therapeutics, Inc. Definitive Proxy Statement
Fulcrum Therapeutics, Inc. has filed its Definitive Proxy Statement (DEF 14A) detailing the agenda for its 2026 annual shareholder meeting on June 24, 2026. Shareholders will vote on the election of three Class I directors (Sonja Banks, Alan Ezekowitz, and Colin Hill), a non-binding advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor. The filing also provides details on executive compensation for 2025, including CEO Alex Sapir's total compensation of $3.25 million, and key 2025 financial results such as a net loss of $74.9 million and $164.2 million raised from a public equity offering.
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has appointed Josh Lehrer, M.D., to its Board of Directors as an independent director. Dr. Lehrer brings over two decades of clinical development experience, including his previous role as CEO of Graphite Bio, Inc. and Chief Medical Officer at Global Blood Therapeutics where he oversaw the development of Oxbryta for sickle cell disease. His expertise in rare disease drug development is expected to be invaluable as Fulcrum advances its pipeline, particularly pociredir for sickle cell disease.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts
Fulcrum Therapeutics (NASDAQ:FULC) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $19.00. This is supported by positive clinical trial data for its drug candidate pociredir and a strong Q1 EPS beat. However, the company remains loss-making, and recent insider and institutional selling have created some negative sentiment.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2026 Earnings Call Transcript
Fulcrum Therapeutics, Inc. reported its Q1 2026 financial results, highlighting positive clinical data from the Phase Ib PIONEER trial for pociredir in sickle cell disease. The company plans to engage with the FDA for an end-of-phase meeting to discuss the design of a potential registration-enabling trial, aiming for initiation in the second half of 2026. Fulcrum also announced a strong balance sheet providing cash runway into 2029 and discussed the competitive landscape, emphasizing the potential of their upstream fetal hemoglobin inducer approach.
Press Release: Fulcrum Therapeutics Appoints Josh Lehrer to Its Board of Directors
Fulcrum Therapeutics has announced the appointment of Josh Lehrer, M.D., M.Phil., to its Board of Directors. Dr. Lehrer brings extensive experience in drug development and rare diseases, currently serving as CEO of Revolution Medicines and having held previous leadership roles at Amgen and Agios Pharmaceuticals. His strategic insight is expected to be valuable as Fulcrum advances its pipeline for rare genetic diseases.
Fulcrum Therapeutics shares climb after Q1 earnings outperform expectations
Fulcrum Therapeutics reported better-than-expected first-quarter earnings, leading to a rise in its share price. The company's financial performance surpassed analyst expectations for the quarter.
Fulcrum Therapeutics shares climb after Q1 earnings outperform expectations
Fulcrum Therapeutics announced robust first-quarter results, surpassing revenue and earnings per share estimates. This positive financial performance indicates strong operational execution and contributed to an increase in the company's stock value.
Fulcrum Therapeutics Inc. (FULC) Tops Q1 EPS by 5c
Fulcrum Therapeutics Inc. (FULC) reported its Q1 EPS, exceeding analyst estimates by $0.05. The company posted an EPS of ($0.25) against an anticipated ($0.30). The article also provides the current stock price and links to further earnings data.
Fulcrum Therapeutics 10-Q: Revenue $0, EPS $(0.25) for Q1 2026
Fulcrum Therapeutics reported no product revenue and a net loss of $18.9 million, or $(0.25) per share, for Q1 2026. Despite the losses, the company highlighted positive clinical progress for its drug candidate pociredir, with strong pharmacodynamic responses and a good safety profile. Management anticipates that current cash and equivalents will fund operations into 2029, supporting ongoing development and potential registration trials.
Fulcrum Therapeutics stock rises nearly 3% on first quarter earnings beat
Fulcrum Therapeutics Inc. reported a first-quarter loss of $0.25 per share, beating analyst estimates, and saw its stock rise by nearly 3% in pre-market trading. The company highlighted positive clinical data for its sickle cell disease drug, pociredir, and plans to initiate a registration-enabling trial in late 2026. Fulcrum maintains a strong financial position, with cash reserves expected to fund operations into 2029.
Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations
Fulcrum Therapeutics Inc. (NASDAQ:FULC) reported first-quarter results that surpassed analyst expectations, leading to a climb in its share price. The company posted a narrower loss per share than forecasted and highlighted encouraging clinical findings for its drug pociredir, with plans for a potential registration-enabling trial in the second half of 2026. Despite increased research and development and general and administrative expenses, Fulcrum maintains a strong cash position expected to fund operations through 2029.
Fulcrum Therapeutics Appoints Dr. Josh Lehrer to Board of Directors
Fulcrum Therapeutics has appointed Dr. Josh Lehrer, a physician-scientist with extensive experience in clinical development and rare disease drug development, to its Board of Directors as an independent director. Dr. Lehrer's background includes leadership roles at Marea Therapeutics, Graphite Bio, and Global Blood Therapeutics, where he oversaw the development and approval of Oxbryta for sickle cell disease. His expertise is expected to be invaluable as Fulcrum advances its lead program, pociredir, aimed at treating sickle cell disease.
Fulcrum Therapeutics adds former Oxbryta developer to board
Fulcrum Therapeutics has appointed Josh Lehrer, former Chief Medical Officer at Global Blood Therapeutics and developer of Oxbryta, to its Board of Directors as an independent director. Lehrer's expertise in rare disease drug development is expected to contribute significantly to Fulcrum, which is focused on developing small molecules for rare hematological disorders. The company's stock has seen a 122% return over the past year, and analysts consider it undervalued despite recent quarterly losses.
Fulcrum Therapeutics (FULC) Expected to Announce Quarterly Earnings on Monday
Fulcrum Therapeutics (NASDAQ:FULC) is scheduled to announce its Q1 2026 earnings before market open on Monday, April 27th, with analysts anticipating an EPS of ($0.31). The stock has a market capitalization of $501.5 million and has seen mixed analyst ratings, though the consensus is a "Moderate Buy" with an average price target of $19. Institutional investors hold a significant portion of the company's shares.
FULC.O PE Ratio & Valuation, Is FULC.O Overvalued
The article provides a valuation analysis for Fulcrum Therapeutics Inc (FULC.O), indicating it is currently in the "Fair zone" based on its forward P/S ratio compared to its five-year average. It details P/B ratio, FCF yield, and comparisons to competitor average P/S ratios, highlighting that its current P/S ratio is unavailable and its robust revenue growth of 0% makes any premium unsustainable. The article also provides answers to frequently asked questions regarding FULC.O's valuation metrics as of April 24, 2026.
FULC Should I Buy
This article analyzes whether to buy Fulcrum Therapeutics Inc (FULC.O) stock, offering insights into analyst ratings and price targets for 2026. It highlights that Wall Street analysts forecast a rise in FULC.O's stock price, with a "Moderate Buy" consensus based on nine buy ratings, one hold, and one sell. Specifically, Truist maintained an $18 price target and a Buy rating, while Stifel's James Condulis maintained a $25 price target and a Buy rating, both based on encouraging data from Fulcrum Therapeutics' PIONEER study for pociredir in sickle cell disease.
Fulcrum schedules April 27 webcast on first-quarter results and updates
Fulcrum Therapeutics will release its first-quarter 2026 financial results on Monday, April 27, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. This announcement follows Fulcrum's established pattern of pre-announcing quarterly calls, and investors will be looking for updates on cash levels, clinical development, and strategy for rare diseases.
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
Fulcrum Therapeutics announced it will host a conference call and webcast on Monday, April 27, 2026, at 8:00 a.m. ET to discuss its first quarter 2026 financial results and provide a corporate update. The financial results will be released before the U.S. financial markets open on the same day. Individuals can register for the call via a provided link or access the audio webcast through the company's investor relations website.
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.9% - Time to Sell?
Fulcrum Therapeutics (NASDAQ:FULC) shares dropped 4.9% on Monday to $7.89, with trading volume significantly below average. The clinical-stage biopharmaceutical company, which focuses on genetic diseases like sickle cell, has a mixed analyst outlook, though the consensus is a "Moderate Buy" with a $19 price target. The stock is currently trading below its 50-day and 200-day moving averages, and institutional investors hold a substantial 89.83% of the company's shares.
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced it will release its first quarter 2026 financial results on Monday, April 27, 2026, before market open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss these results and provide updates on corporate developments. An archived replay will be available after the live webcast.
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Grows By 41.1%
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) experienced a 41.1% increase in short interest during March, reaching 6,962,035 shares, representing 11.2% of the stock. This elevated bearish sentiment is coupled with a short-interest ratio of 4.6 days, hinting at potential short-squeeze dynamics. Despite mixed analyst views, the company holds a "Moderate Buy" consensus rating with a $19 target price, and a high institutional ownership of nearly 90%.
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Fulcrum Therapeutics (NASDAQ:FULC) from a "sell" to a "strong sell." Despite this, MarketBeat's consensus rating for FULC remains a "Moderate Buy" with an average price target of $19.00, reflecting mixed analyst opinions. The stock is currently trading around $7.55, with institutional investors holding a significant portion of its shares.
Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy Recommendation
Truist Securities has initiated coverage of Fulcrum Therapeutics (FULC) with a "Buy" recommendation. This new coverage suggests a positive outlook from the firm regarding Fulcrum Therapeutics' future performance.
Fulcrum Therapeutics Inc (FULC) Stock Price Quote Today & Current Price Chart
This page provides current stock price quotes and chart information for Fulcrum Therapeutics Inc (FULC), a clinical-stage biopharmaceutical company. It details FULC's medical focus on genetically defined diseases, including its lead product candidates losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease and β-thalassemia. The article also includes trading conditions for CFDs, key financial statistics, and recent related market news.
Vanguard entities disaggregate Fulcrum holdings (FULC) after internal realignment
The Vanguard Group has filed an Amendment No. 2 to a Schedule 13G/A, reporting 0 shares beneficially owned and 0% of common stock in Fulcrum Therapeutics Inc (FULC) as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, which caused certain Vanguard subsidiaries to report their beneficial ownership separately. The filing clarifies that this is a procedural change in reporting rather than an indication of market transactions or sales of shares.
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index
Fulcrum Therapeutics, Inc. (NasdaqGM:FULC) has been added to the S&P Pharmaceuticals Select Industry Index. This news follows several other recent announcements from the company, including positive results from its Phase 1b PIONEER trial for Pociredir in sickle cell disease and an analyst initiation with an "Overweight" rating. The company focuses on developing treatments for genetically defined rare diseases.
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
MedicAlert Foundation, the Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics have partnered to enhance emergency department (ED) care for individuals with sickle cell disease (SCD). This collaboration aims to expedite access to patient-specific care plans during pain crises through MedicAlert Smart Medical ID Cards, which provide critical health information to clinicians. The program seeks to address barriers to timely and compassionate care for the 100,000 people in the U.S. affected by SCD.
QR medical ID cards aim to speed ER care during sickle cell pain crises
Fulcrum Therapeutics, the MedicAlert Foundation, and the Sickle Cell Disease Association of America (SCDAA) have partnered to accelerate emergency department care for individuals with sickle cell disease (SCD). This three-year collaboration focuses on providing MedicAlert Smart Medical ID Cards, which leverage QR codes to give ER clinicians immediate access to critical patient-specific care plans, including pain management strategies, hematologist contacts, medications, and allergies. The initiative aims to reduce delays and improve the quality of care during acute pain crises for the estimated 100,000 people living with SCD in the U.S.
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
MedicAlert Foundation, the Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics have partnered to streamline emergency department care for individuals with sickle cell disease (SCD). This three-year collaboration aims to provide rapid access to patient-specific care plans via a MedicAlert Smart Medical ID Card, helping clinicians deliver timely and targeted care during pain crises. The initiative seeks to address barriers to appropriate care and improve care coordination for the 100,000 people affected by SCD in the U.S.
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Rises By 19.7%
Short interest in Fulcrum Therapeutics (NASDAQ:FULC) rose by 19.7% in February, reaching 4,210,945 shares. This represents 6.8% of the company's shares sold short, with a short-interest ratio of 3.8 days. Insiders own 7% of the stock, while institutional investors hold nearly 90%, including recent increases from major firms.
Boothbay Fund Management Increases Stake in Fulcrum Therapeutics
Boothbay Fund Management LLC significantly increased its stake in Fulcrum Therapeutics (NASDAQ:FULC) by 104.2% during the third quarter, now owning 678,414 shares. This move suggests the hedge fund sees considerable potential in the clinical-stage biotech company's pipeline and future prospects. The investment highlights confidence in Fulcrum Therapeutics' focus on developing treatments for genetic diseases.
Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC
Boothbay Fund Management LLC significantly increased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 104.2% in the third quarter, now owning 678,414 shares worth $6.24 million. Other hedge funds like Cubist Systematic Strategies and Jane Street Group LLC also modified their holdings, with institutional investors now owning 89.83% of the stock. Analyst ratings for FULC are mixed, with an average "Moderate Buy" rating and a target price of $19.00, while insider trading shows a director selling 15,000 shares.
Wall Street analysts think Fulcrum Therapeutics (FULC) could surge 58.47%: Read this before placing a bet
This article from MSN discusses Fulcrum Therapeutics (FULC) and its potential stock surge based on Wall Street analysts' price targets. Analysts project a 58.47% upside for the stock, indicating strong confidence in the company's future performance. Investors are advised to review this analysis before making any investment decisions regarding FULC.
219,488 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by Braidwell LP
Braidwell LP recently acquired 219,488 shares of Fulcrum Therapeutics (NASDAQ:FULC) in the third quarter, a new stake valued at approximately $2.02 million and representing 0.41% of the company. Institutional investors and hedge funds own a significant portion of the stock, while insiders like director Robert J. Gould have recently sold shares. Analysts currently have a "Moderate Buy" rating for Fulcrum Therapeutics with an average price target of $19.
Suvretta Capital Management LLC Raises Holdings in Fulcrum Therapeutics, Inc. $FULC
Suvretta Capital Management LLC increased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 5.9% in the third quarter, bringing its total holdings to 5,381,000 shares valued at approximately $49.5 million. Other institutional investors also adjusted their positions in the company. Fulcrum Therapeutics, which has a market cap of about $509 million and a beta of 3.23, is rated a "Moderate Buy" by analysts with an average target price of $19.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, a biopharmaceutical company, announced it granted stock options to a new employee as an inducement for employment, as per Nasdaq Listing Rule 5635(c)(4). This grant includes 34,000 options to purchase common stock at an exercise price of $7.81 per share, vesting over four years. The company specializes in developing small molecules for genetically defined rare diseases.
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Leerink Partners Global Healthcare Conference. Management will present on March 10, 2025, at 1:00 p.m. ET in Miami, FL. A webcast of the presentation will be available on the company's website, with a replay accessible for at least 30 days.
